Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by Epstein-Barr virus and human papillomaviruses: With special reference to oral cancer

Oral Oncology

Volumn 51, Issue 8, 2015, Pages 731-737

  Chawla, Jatinder Pal Singh ^a   Iyer, Nageshwar ^a   Soodan, Kanwaldeep Singh ^a   Sharma, Atul ^a   Khurana, Sunpreet Kaur ^b   Priyadarshni, Pratiksha ^a  

^a M M COLLEGE OF DENTAL SCIENCES AND RESEARCH   (India)

^b Swami Devi Dyal Hospital and Dental College   (India)

Author keywords

BARTs; Biomarker; Cellular expression; EBV; Gene expression; HPV; MicroRNA; miRNA; Oral cancer; Therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; TRANSCRIPTION FACTOR; TUMOR PROTEIN; TUMOR MARKER;

BIOGENESIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; EPIGENETICS; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; HIGH RISK PATIENT; HUMAN; METASTASIS; MOUTH SQUAMOUS CELL CARCINOMA; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; WART VIRUS; GENETICS; MOUTH NEOPLASMS; PROGNOSIS;

BIOMARKERS, TUMOR; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MICRORNAS; MOUTH NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS;

EID: 84942821687     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.05.008     Document Type: Review

References (82)

1. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008;45(2):553-63.
2. Mattick JS, Makunin IV, Non-coding RNA. Hum Mol Genet 2006;15:17-29.
3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
4. Cheng G, Danquah M, Mahato RI. MicroRNAs as therapeutic targets for cancer. New York: Springer; 2009.
5. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci 2012;37:460-5.
6. Lopez-Serra P, Esteller M. DNA methylation-associated silencing of tumorsuppressor microRNAs in cancer. Oncogene 2012;31:1609-22.
7. Melo SA, Kalluri R. Molecular pathways: microRNAs as cancer therapeutics. Clin Cancer Res 2012;18:4234-9.
8. Shen J, Stass SA, Jiang F. MicroRNAs as potential biomarkers in human solid Tumors. Cancer Lett 2013;329:125-36.
9. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C elegans. Cell 1993;75:855-62.
10. Chen X, Gong J, Zeng H, Chen N, Huang R, et al. MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 2010;70:2728-38.
11. Huppi K, Volfovsky N, Mackiewicz M, et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007;17:65-73.
12. Ling H, Zhang W, Calin GA. Principles of microRNA involvement in human cancers. Chin J Cancer 2011;30:739-48.
13. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
14. Siomi H, Siomi MC. Posttranscriptional regulation of microRNAs biogenesis in animals. Mol Cell 2010;38:323-32.
15. Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA sequences in human disease. Mutat Res 2012;731:14-9.
16. Yi R et al. DGCR8-dependent microRNA biogenesis is essential for skin development. Proc Natl Acad Sci USA 2009;106:498-502.
17. Cordes KR et al. MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705-10.
18. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6:590-610.
19. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006;66:7390-4.
20. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: microRNAs in cancer. Cell 2009;137:586.
21. Fabbri M et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-10.
22. Ryland GL et al. MicroRNA genes and their target 30-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS ONE 2012;7:e35805.
23. Wu M et al. Genetic variations of microRNAs in human cancer and their effects on the expression of miRNAs. Carcinogenesis 2008;29:1710-6.
24. Tian T et al. A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prev 2009;18:1183-7.
25. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumorsuppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008;68:2094-105.
26. Wiklund ED et al. MicroRNA alterations and associated aberrant DNA methylation patterns across multiple sample types in oral squamous cell carcinoma. PLoS ONE 2011;6:e27840.
27. Langevin SM et al. MicroRNA-137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck. Cancer 2011;117:1454-62.
28. Hu H et al. The overexpression of hypomethylated miR-663 induces chemotherapy resistance in human breast cancer cells by targeting heparin sulfate proteoglycan 2 (HSPG2). J Biol Chem 2013;288:10973-85.
29. Dang J et al. MicroRNA-137 promoter methylation in oral lichen planus and oral squamous cell carcinoma. J Oral Pathol Med 2013;42:315-21.
30. Ha PK, Califano JA. Promoter methylation and inactivation of tumoursuppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006;7:77-82.
31. Minor J et al. Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol 2012;48:73-8.
32. Wee EJ et al. Mapping the regulatory sequences controlling 93 breast cancerassociated miRNA genes leads to the identification of two functional promoters of the Hsa-mir-200b cluster, methylation of which is associated with metastasis or hormone receptor status in advanced breast cancer. Oncogene 2012;31:4182-95.
33. Zhang X et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012;22:506-23.
34. Nohata N et al. Tumour-suppressive microRNA-874 contributes to cell proliferation through targeting of histone deacetylase 1 in head and neck squamous cell carcinoma. Br J Cancer 2013;108:1648-58.
35. Jakymiw A et al. Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer 2010;49:549-59.
36. Chiosea S et al. Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006;169. 1812-20.
37. Karube Y et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005;96:111-5.
38. MerrittWMet al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008;359:2641-50.
39. Ma H et al. Genetic variations in key microRNA processing genes and risk of head and neck cancer: a case-control study in Chinese population. PLoS ONE 2012;7:e47544.
40. Frenzel A, Loven J, Henriksson MA. Targeting MYC-regulated miRNAs to combat cancer. Genes Cancer 2010;1:660-7.
41. Waitzberg AF et al. Clinical significance of c-myc and p53 expression in head and neck squamous cell carcinomas. Cancer Detect Prev 2004;28:178-86.
42. Agrawal N et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
43. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408: 307-10.
44. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003;39:222-31.
45. Ganci F et al. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol 2013;24:3082-8.
46. Liu CJ et al. MiR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma. Cancer Res 2010;70:1635-44.
47. Christensen BC et al. A let-7 microRNA-binding site polymorphism in the KRAS 30 UTR is associated with reduced survival in oral cancers. Carcinogenesis 2009;30:1003-7.
48. Guan X et al. A functional variant at the miR-885-5p binding site of CASP3 confers risk of both index and second primary malignancies in patients with head and neck cancer. FASEB J 2013;27:1404-12.
49. Liu X et al. MicroRNA-24 targeting RNA-binding protein DND1 in tongue squamous cell carcinoma. FEBS Lett 2010;584:4115-20.
50. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of Ecadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-4.
51. Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celiá-Terrassa T, et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat Med 2011;17:1101-8.
52. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down modulation. Proc Natl Acad Sci USA 2005;102:18081-6.
53. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. MiR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci USA 2010;107:264-9.
54. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
55. Santarpia L, Nicoloso M, Calin GA. MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. Endocrine-Relat Cancer 2010;17:F51-75.
56. Tran N, McLean T, Zhang X, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007;358:12-7.
57. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci USA 2008;105:3945-50.
58. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
59. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
60. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011;8:467-77.
61. Liu CJ, Lin SC, Yang CC, Cheng HW, Chang KW. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma. Head Neck 2012;34:219-24.
62. Maclellan SA et al. Differential expression of miRNAs in the serum of patients with high-risk oral lesions. Cancer Med 2012;1:268-74.
63. Park NJ et al. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009;15:5473-7.
64. Jung H, Shin Y. The potential RNAi-based combination therapeutics. Arch Pharm Res 2011;34:1-2.
65. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
66. Davison AJ, Eberle R, Ehlers B, Hayward GS, McGeoch DJ, Minson AC, et al. The order Herpes virales. Arch Virol 2009;154:171-7.
67. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, Ju J, et al. Identification of virus-encoded microRNAs. Science 2004;304:734-6.
68. Zhu JY, Pfuhl T, Motsch N, Barth S, Nicholls J, Grasser F, et al. Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. J Virol 2009;83:3333-41.
69. Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathogen 2010:6.
70. Lo AK, To KF, Lo KW, Lung RW, Hui JW, Liao G, et al. Modulation of LMP1 protein expression by EBV-encoded microRNAs. Proc Natl Acad Sci USA 2007;104:16164-9.
71. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med 2008;205:2551-60.
72. Barth S, Pfuhl T, Mamiani A, Ehses C, Roemer K, Kremmer E, et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucl Acids Res 2008;36:666-75.
73. Lung RW, Tong JH, Sung YM, Leung PS, Ng SC, Chau SL, et al. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009;11:1174-84.
74. Kimdo N, Chae HS, Oh ST, Kang JH, Park CH, Park WS, et al. Expression of viral microRNAs in Epstein-Barr virus-associated gastric carcinoma. J Virol 2007;81:1033-6.
75. Wong AM, Kong KL, Tsang JW, Kwong DL, Guan XY. Profiling of Epstein-Barr virus-encoded microRNAs in nasopharyngeal carcinoma reveals potential biomarkers and oncomirs. Cancer 2011;118(3):698-710.
76. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and posttranscriptional regulation. Front Biosci 2006;11:2286-302.
77. Grassmann R, Jeang KT. The roles of microRNAs in mammalian virus infection. Biochim Biophys Acta 2008;1779:706-11.
78. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010;84:5212-21.
79. Nuovo GJ, Wu X, Volinia S, Yan F, Di Leva G, Chin N, et al. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn. Mol. Pathol. 2010;19:135-43.
80. Nishida N, Mimori K, Fabbri M, Yokobori T, Sudo T, Tanaka F, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with Trastuzumab. Clin Cancer Res 2011;17:2725-33.
81. Peng S et al. Association of microRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci 2010;55:2288-93.
82. Zhang X et al. MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 2010;31:2118-23.